Eli Lilly sues six sellers of unapproved retatrutide copies
Targets include four research-peptide vendors, a California med spa and Striker Pharmacy, which the company says compounded a version of the unapproved drug.
DO
By Daniel Okafor · Regulatory Correspondent
Aug 12 03:00 ETSource: CBS News
The wire
- 01Lilly filed suits against Astra Peptides, Legendary Peptides, Texas Peptides, Lone Star Peptide, med spa Aesthetic Envy and Striker Pharmacy over sales of retatrutide, which is still in late-stage trials.
- 02Research-peptide vendors and compounders now face direct litigation risk for marketing an unapproved molecule; Lone Star, Texas Peptides and Aesthetic Envy pulled their retatrutide pages.
- 03Lilly says overseas manufacturers supply the market and plans to seek approval in early 2027; the defendants did not respond to requests for comment.
From the source
Read at cbsnews.comEli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit market .